* MacroGenics Inc is expected to show a rise in quarterly revenue when it reports results on November 5 for the period ending January 1 0001
* The Rockville Maryland-based company is expected to report a 632.1% increase in revenue to $76.115 million from $10.4 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
* LSEG's mean analyst estimate for MacroGenics Inc is for earnings of 21 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for MacroGenics Inc is $8.00, above its last closing price of $3.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.54 -0.59 -0.89 Missed -51.2
Jan. 1 0001 -0.64 -0.64 -0.84 Missed -30.7
Jan. 1 0001 -0.26 -0.15 -0.75 Missed -388
Sep. 30 2023 -0.06 -0.10 0.28 Beat 392.9
Jun. -0.47 -0.52 -0.69 Missed -32.4
30 2023
Mar. 31 2023 0.42 0.45 -0.61 Missed -234.9
Jan. 1 0001 -0.07 0.10 0.21 Beat 105.7
Sep. 30 2022 -0.36 -0.38 -0.40 Missed -4.2
This summary was machine generated November 2 at 03:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。